Book contents
- Transient Ischemic Attack and Stroke
- Transient Ischemic Attack and Stroke
- Copyright page
- Contents
- Preface to the Second Edition
- Section 1 Epidemiology, Risk Factors, Pathophysiology, and Causes of Transient Ischemic Attacks and Stroke
- Section 2 Clinical Features, Diagnosis, and Investigation
- Section 3 Prognosis of Transient Ischemic Attack and Stroke
- Section 4 Treatment of Transient Ischemic Attack and Stroke
- Chapter 18 Methods of Assessing Treatments
- Chapter 19 Acute Treatment of Transient Ischemic Attack and Minor Stroke
- Chapter 20 Acute Treatment of Major Stroke: General Principles
- Chapter 21 Specific Treatments for Major Acute Ischemic Stroke
- Chapter 22 Specific Treatment of Acute Intracerebral Hemorrhage
- Chapter 23 Recovery and Rehabilitation after Stroke
- Section 5 Secondary Prevention
- Section 6 Miscellaneous Disorders
- Index
- References
Chapter 18 - Methods of Assessing Treatments
from Section 4 - Treatment of Transient Ischemic Attack and Stroke
Published online by Cambridge University Press: 01 August 2018
Book contents
- Transient Ischemic Attack and Stroke
- Transient Ischemic Attack and Stroke
- Copyright page
- Contents
- Preface to the Second Edition
- Section 1 Epidemiology, Risk Factors, Pathophysiology, and Causes of Transient Ischemic Attacks and Stroke
- Section 2 Clinical Features, Diagnosis, and Investigation
- Section 3 Prognosis of Transient Ischemic Attack and Stroke
- Section 4 Treatment of Transient Ischemic Attack and Stroke
- Chapter 18 Methods of Assessing Treatments
- Chapter 19 Acute Treatment of Transient Ischemic Attack and Minor Stroke
- Chapter 20 Acute Treatment of Major Stroke: General Principles
- Chapter 21 Specific Treatments for Major Acute Ischemic Stroke
- Chapter 22 Specific Treatment of Acute Intracerebral Hemorrhage
- Chapter 23 Recovery and Rehabilitation after Stroke
- Section 5 Secondary Prevention
- Section 6 Miscellaneous Disorders
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Transient Ischemic Attack and StrokeDiagnosis, Investigation and Treatment, pp. 265 - 281Publisher: Cambridge University PressPrint publication year: 2018
References
Anturane Reinfarction Trial Research Group (1980). Sulfinpyrazone in the prevention of sudden death after myocardial infarction. New England Journal of Medicine 302:250–256Google Scholar
Asymptomatic Carotid Atherosclerosis Study Group (1995). Carotid endarterectomy for patients with asymptomatic internal carotid artery stenosis. Journal of the American Medical Association 273:1421–1428CrossRefGoogle Scholar
Barnett, HJ, Taylor, DW, Eliasziw, M et al. (1998). The final results of the NASCET trial. New England Journal of Medicine 339:1415–1425CrossRefGoogle Scholar
Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989). Preliminary report: Effect of encainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. New England Journal of Medicine 321:406–412Google Scholar
Charlson, ME, Horwitz, RI (1984). Applying results of randomised trials to clinical practice: Impact of losses before randomisation. British Medical Journal 289:1281–1284CrossRefGoogle ScholarPubMed
Coronary Drug Project Research Group (1980). Influence of adherence to treatment and response to cholesterol on mortality in the Coronary Drug Project. New England Journal of Medicine 303:1038–1041Google Scholar
Dahlof, B, Lindholm, LH, Hansson, L et al. (1991). Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-hypertension). Lancet 338:1281–1285CrossRefGoogle ScholarPubMed
Davis, KL, Thal, LJ, Gamzu, ER et al. (1992). A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. New England Journal of Medicine 321:406–412Google Scholar
Farrell, B, Godwin, J, Richards, S et al. (1991). The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results. Journal of Neurology, Neurosurgery and Psychiatry 54:1044–1054CrossRefGoogle ScholarPubMed
Fine, PEM (1995). Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346:1339–1345CrossRefGoogle ScholarPubMed
Gorter, JW for the Stroke Prevention in Reversible Ischaemia Trial (SPIRIT) and European Atrial Fibrillation Trial (EAFT) Groups (1999). Major bleeding during anticoagulation after cerebral ischaemia: Patterns and risk factors. Neurology 53:1319–1327CrossRefGoogle ScholarPubMed
Gøtzsche, PC (1989). Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control in Clinical Trials 10:31–56Google Scholar
Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI) (1986). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet i:397–402Google Scholar
Gurwitz, JH, Col, NF, Avorn, J (1992). The exclusion of elderly and women from clinical trials in acute myocardial infarction. Journal of the American Medical Association 268:1417–1422Google Scholar
Ioannidis, JP, Contopoulos-Ioannidis, DG (1998). Reporting of safety data from randomised trials. Lancet 352:1752–1753CrossRefGoogle ScholarPubMed
Jorgensen, HS, Nakayama, H, Kammersgaard, LP et al. (1999). Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: Simulation model. British Medical Journal 319:288–289Google Scholar
LaRue, LJ, Alter, M, Traven, ND et al. (1988). Acute stroke therapy trials: Problems in patient accrual. Stroke 19:950–954Google Scholar
Marshall, M, Lockwood, A, Bradley, C et al. (2000). Unpublished rating scales: A major source of bias in randomised controlled trials of treatments for schizophrenia? British Journal of Psychiatry 176:249–252CrossRefGoogle Scholar
Medical Research Council Working Party (1985). MRC trial of treatment of mild hypertension: Principal results. British Medical Journal 291:97–104Google Scholar
Noseworthy, JH, Ebers, GC, Vandervoort, MK et al. (1994). The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 44:16–20CrossRefGoogle ScholarPubMed
Pincus, T (1998). Rheumatoid arthritis: Disappointing long-term outcomes despite successful short-term clinical trials. Journal of Clinical Epidemiology 41:1037–1041CrossRefGoogle Scholar
Riggs, BL, Hodgson, SF, O’Fallon, WM et al. (1990). Effect of fluoride treatment on fracture rate in postmenopausal women with osteoporosis. New England Journal of Medicine 322:802–809Google Scholar
Rothwell, PM (2005a). External validity of randomised controlled trials: To whom do the results of this trial apply? Lancet 365:82–93Google Scholar
Rothwell, PM (2005b). Subgroup analysis in randomised controlled trials: Importance, indications and interpretation. Lancet 365:176–186Google Scholar
Rothwell, PM, Giles, MF, Chandratheva, A et al. (2007). Major reduction in risk of early recurrent stroke by urgent treatment of TIA and minor stroke: EXPRESS Study. Lancet 370:1432–1442Google Scholar
Shapiro, SH, Weijer, C, Freedman, B (2000). Reporting the study populations of clinical trials. Clear transmission or static on the line? Journal of Clinical Epidemiology 53:973–979Google Scholar
Taylor, DW, Barnett, HJM, Haynes, RB et al. (1999). Low dose and high dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial. Lancet 353:2179–2184Google Scholar
Temple, R, Pledger, GW (1980). The FDA’s critique of the Anturane Reinfarction Trial. New England Journal of Medicine 303:1488–1492Google Scholar
Thornley, B, Adams, CE (1998). Content and quality of 2000 controlled trials in schizophrenia over 50 years. British Medical Journal 317:1181–1184Google Scholar